Showing results (71-80 of 241) with videos related to

Sort By:
Pageof 25
The Oncologist|June 10, 2015
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody CixutumumabNaifa L Busaidy, Patricia LoRusso, Kristie Lawhorn, et al.
Investigational New Drugs|August 3, 2013
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignanciesGerald S Falchook, Siqing Fu, Aung Naing, et al.
Molecular Cancer Therapeutics|August 22, 2013
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutationsJennifer J Wheler, Apostolia M Tsimberidou, Gerald S Falchook, et al.
Cancer Chemotherapy and Pharmacology|February 11, 2015
Phase I trial of valproic acid and lenalidomide in patients with advanced cancerMehmet Asim Bilen, Siqing Fu, Gerald S Falchook, et al.
Cancers|August 23, 2020
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and ParagangliomasCamilo Jimenez, Vivek Subbiah, Bettzy Stephen, et al.
Investigational New Drugs|March 31, 2015
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancerDavid S Hong, Filip Janku, Aung Naing, et al.
Investigational New Drugs|September 1, 2021
A phase i study of ixazomib and erlotinib in patients with advanced solid tumorsShumei Kato, Jacob J Adashek, Vivek Subbiah, et al.
Oncotarget|June 27, 2013
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I populationJennifer Wheler, Gerald Falchook, Apostolia M Tsimberidou, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 16, 2015
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumorsGerald S Falchook, Karthik Venkatakrishnan, John Sarantopoulos, et al.
Cancers|August 12, 2022
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical TrialsJeffrey A How, Amir A Jazaeri, Siqing Fu, et al.
Pageof 25